14-day Premium Trial Subscription Sign Up For FreeGet Free

Arbutus Biopharma Corporation Stock Forecast NASDAQ:ABUS

Price Target and Analyst Ratings

Most Recent Rating

On August 31, 2021 "Chardan Capital" gave "" rating for ABUS. The price target was set to $3.38+1.5%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-31 Reiterated by Chardan Capital $3.43 $3.38+1.5%
2021-03-10 Buy Target Lowered by B. Riley $3.64 $8.00 → $7.00
2021-03-10 Buy Reiterated by B. Riley $3.64 $8.00 → $7.00
2021-03-10 Buy Reiterated by HC Wainwright $3.64 $10.00
2021-02-25 Hold Initiated by Jefferies Financial Group $3.81 $5.00
2020-12-17 Buy Initiated by HC Wainwright $4.73 $10.00
2020-11-16 Buy Reiterated by Chardan Capital $3.63 $5.00
2020-07-27 Outperform Initiated by JMP Securities $4.47 $10.00 → $8.00
2020-07-27 Target Raised by B. Riley $4.47 $6.00 → $8.00
2020-07-24 Outperform - Neutral Downgraded by Robert W. Baird $4.96
2020-05-19 Neutral - Outperform Upgraded by Wedbush $2.31 $2.00 → $4.00
2020-05-19 Buy Reiterated by B. Riley $2.31 $6.00
2020-05-13 Buy Reiterated by Chardan Capital $1.70 $5.00

ABUS Stock Trend

The stock lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $4.51 will firstly indicate a stronger rate of rising.

Given the current short-term trend, the stock is expected to rise 33.56% during the next 3 months and, with a 90% probability hold a price between $4.36 and $6.02 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-23 $3.28 $3.90 $4.52
2021-09-24 $3.30 $3.92 $4.54
2021-09-27 $3.32 $3.94 $4.56
2021-09-28 $3.34 $3.96 $4.58
2021-09-29 $3.36 $3.98 $4.60
2021-09-30 $3.37 $3.99 $4.61
2021-10-01 $3.39 $4.01 $4.63
2021-10-04 $3.41 $4.03 $4.65
2021-10-05 $3.43 $4.05 $4.67
2021-10-06 $3.45 $4.07 $4.69
2021-10-07 $3.46 $4.08 $4.70
2021-10-08 $3.48 $4.10 $4.72
2021-10-11 $3.50 $4.12 $4.74
2021-10-12 $3.52 $4.14 $4.76
2021-10-13 $3.53 $4.16 $4.78
2021-10-14 $3.55 $4.17 $4.79
2021-10-15 $3.57 $4.19 $4.81
2021-10-18 $3.59 $4.21 $4.83
2021-10-19 $3.61 $4.23 $4.85
2021-10-20 $3.62 $4.24 $4.87
2021-10-21 $3.64 $4.26 $4.88
2021-10-22 $3.66 $4.28 $4.90
2021-10-25 $3.68 $4.30 $4.92
2021-10-26 $3.70 $4.32 $4.94
2021-10-27 $3.71 $4.33 $4.96
2021-10-28 $3.73 $4.35 $4.97
2021-10-29 $3.75 $4.37 $4.99
2021-11-01 $3.77 $4.39 $5.01
2021-11-02 $3.79 $4.41 $5.03
2021-11-03 $3.80 $4.42 $5.04

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT